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The mammalian epidermal growth factor (EGF) is expressed in
the developing and adult CNS, and it has been implicated in the
control of cell proliferation, differentiation, and neurotrophic
events. Despite extensive evolutionary conservation of the EGF
motif in a range of different types of proteins, secreted EGF
homologs with neurotrophic actions have not been reported in
invertebrates. In this study, we present a novel member of the
family of EGF-like growth factors, an EGF homolog from the
mollusc Lymnaea stagnalis (L-EGF), and we demonstrate that
this protein has neurotrophic activity. Purified L-EGF is a 43-
residue peptide and retains the typical structural characteristics
of the EGF motif. The L-EGF cDNA reveals a unique precursor
organization. In contrast to the multidomain mammalian EGFs, it
consists of only two domains, a signal peptide and a single EGF
motif. Conspicuously, the L-EGF precursor lacks a transmem-
brane domain, setting it apart from all other members of the
EGF-family. L-EGF mRNA is expressed throughout embryonic
development, in the juvenile CNS, but not in the normal adult
CNS. However, expression in the adult CNS is upregulated after
injury, suggesting a role of L-EGF in repair functions. This notion
is supported by the observation that L-EGF evokes neurite out-
growth in specific adult Lymnaea neurons in vitro, which could be
inhibited by an EGF receptor tyrosine kinase inhibitor. In conclu-
sion, our findings further substantiate the notion that the EGF
family has an early phylogenetic origin, and our data support a
neurotrophic role for L-EGF during development and injury repair.
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Epidermal growth factor (EGF), a member of the EGF growth
factor family, is expressed in the developing and adult CNS (Rall et
al., 1985; Schaudies et al., 1989; Lazar and Blum, 1992). Mamma-
lian EGF is a polypeptide consisting of 53 amino acid residues
characterized by six cysteine residues arranged in a conserved
pattern of three disulfide bonds and three characteristic C-terminal
amino acids (the EGF motif) (Carpenter and Cohen, 1990). This
secreted polypeptide is the product of the proteolytic processing of
a large, multi-domain transmembrane EGF precursor protein
(Carpenter and Cohen, 1990; Plata-Salama´n, 1991; Yamada et al.,
1997). The EGF motif is present in many other multi-domain
proteins throughout the animal kingdom, including a number of
EGF family members, such as transforming growth factor a
(TGFa) and amphiregulin (Engel, 1989; Carpenter and Cohen,
1990; Davis, 1990; Greenwald, 1990; Muskavitch and Hoffmann,
1990; Yamada et al., 1997). Although TGFa homologs have been
found in Drosophila (e.g., spitz and gurken; Rutledge et al., 1992;
Neuman-Silberberg and Schu¨pbach, 1993), secreted forms of EGF
itself have so far only been reported in mammals.
The present study was motivated by the observation that human
EGF (hEGF) induces neurite outgrowth in motoneurons of the
pond snail Lymnaea stagnalis. This result and the apparent conser-
vation of the EGF motif prompted us to investigate the existence of
an EGF homolog in Lymnaea. Although Lymnaea has been suc-
cessfully used over the last decade to identify growth factor recep-
tors (Roovers et al., 1995; Van Kesteren et al., 1998) and to
characterize novel neuromodulatory actions of neurotrophic fac-
tors (Wildering et al., 1995; Fainzilber et al., 1996), attempts to
identify endogenous growth factors have so far remained primarily
unsuccessful. The single exception to this rule is cysteine-rich
neurotrophic factor (Fainzilber et al., 1996). In this regard, it is of
particular interest to investigate the existence of Lymnaea EGF
homologs and their physiological activity.
In the present study, we purified, cloned, and characterized an
EGF homolog, Lymnaea EGF (L-EGF) from the Lymnaea albu-
men gland, an organ that secretes fluid surrounding fertilized
oocytes (Joosse and Geraerts, 1983). We show that L-EGF is a
secreted growth factor with a surprisingly simple precursor orga-
nization. L-EGF selectively induces neurite outgrowth in adult
Lymnaea neurons in vitro. An endogenous role for L-EGF in
neuronal development and regeneration is suggested by the fact
that, in addition to expression in the albumen gland, mRNA
expression for this factor is highest during embryogenesis, in juve-
nile brains, and is upregulated in adult CNS after axotomy. This
study shows for the first time that a secreted homolog of the peptide
EGF is present in an invertebrate species and likely plays a neu-
rotrophic role during development and axonal regeneration of
adult neurons.
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MATERIALS AND METHODS
Peptide extraction and purification of L-EGF. L-EGF was purified from
extracts of ;500 albumen glands in batches of 10–20 glands. Albumen glands
were removed from the adult gastropod mollusc L. stagnalis, lyophilized,
extracted at 4°C in 0.1% heptafluorobutyric acid (HFBA) (Pierce, Rockford,
IL) using a Polytron homogenizer (Brinkmann Instruments, Inc., Westbury,
NY), and sonicated. The extract was centrifuged for 20 min at 48,000 3 g
(4°C), and the supernatant was purified on four C18 Sep-Pak cartridges
(Waters Associates, Milford, MA) connected in series; Sep-Paks were pre-
treated with 5 ml of 100% acetonitrile (ACN) containing 0.1% HFBA and
rinsed with 10 ml of 0.1% HFBA. The peptides were eluted with 5 ml of 50%
ACN containing 0.1% HFBA and lyophilized. The lyophilizate was resus-
pended in 2.5 ml of 0.1% HFBA and applied to an analytical C18 reversed-
phase (RP)-HPLC column (4.6 3 250 mm; Vydac, Hesperia, CA). The
column was eluted with a two-step linear gradient of 0.1% HFBA
and ACN containing 0.1% HFBA. The first step was 0–10% ACN con-
taining 0.1% HFBA in 5 min, and the second step was 10–34% ACN
containing 0.1% HFBA in 85 min. The column eluate was monitored at
214 nm, and 1 min (1 ml) fractions were collected. For chemical charac-
terization studies, fractions containing L-EGF were pooled, lyophilized,
reduced with 2-mercaptoethanol, alkylated with 4-vinylpyridine (Pierce)
(Hawke and Yuan, 1987; Coligan et al., 1996), and purified by Vydac C18
RP-HPLC. The same gradient conditions were used as described above,
except that 0.1% trifluoroacetic acid (TFA) (Pierce) was the counterion.
The peak of interest was characterized by amino acid compositional and
microsequence analysis. For bioassays studies, fractions containing L-EGF
were not reduced and alkylated before Vydac C18 RP-HPLC. Approxi-
mately 175 pmol of L-EGF were obtained per gland.
Amino acid compositional analysis of L-EGF. Reagents for these analyses
were purchased from PE/Applied Biosystems (Foster City, CA). Compo-
sitional analyses were performed using a PE/Applied Biosystems 420H
Amino Acid Analyzer (Smith et al., 1991).
Edman microsequence analysis of L-EGF. For Edman degradations of
L-EGF, formic acid-treated L-EGF, and Glu-C peptides, samples were
applied to Biobrene Plus-treated glass fiber filters and subjected to auto-
mated N-terminal sequence analysis using a PE/Applied Biosystems Pro-
cise 494/HT Protein Sequencer. Pulsed liquid cycles were used for each
analysis. Edman degradations of tryptic and pyroglutamate aminopepti-
dase (PGAP) peptides were performed using a PE/Applied Biosystems
477A Protein Sequencer connected to an on-line 120A Analyzer using
sequencing protocols specified by, and reagents from, the instrument
manufacturer. Data analyses were conducted by direct inspection of on-
line analog chart recordings and compared with phenylthiohydantion-
amino acid standards. Amino acid sequence analysis demonstrated that the
peptide was blocked at the N terminus, and initial attempts to unblock
the peptide were unsuccessful. Therefore, the glass fiber filter containing
the reduced and alkylated peptide was placed back into a sequencer
reaction cartridge, 15 ml of 1 mM cyanogen bromide in 70% formic acid was
added, and the filter containing the peptide was incubated in the sequencer
for 2 hr at 70°C under argon. The filter was dried with argon and then
sequenced using normal pulsed liquid chemistry. Microsequence analysis
revealed a partial 34-residue sequence corresponding to residues 7–40.
The partial sequence indicated a Pro residue at position 1 of the 34-residue
sequence, suggesting that an Asp-Pro bond was cleaved by the formic acid
treatment. This was confirmed by incubation with 70% formic acid alone at
21°C, followed by microsequence analysis, which generated an identical
sequence for the first 10 cycles. Formic acid cleavage of the Asp 6-Pro 7
bond (and Asp 41-Pro 42 bond; see below) presumably generated a 35-
residue peptide (residue 7–41). To extend these data, fraction 1 was
digested with endoproteinase Glu-C, and the resulting peptides were
purified by RP-HPLC. Microsequence analysis of one peptide (residues
30–43) extended the C-terminal sequence by an additional three residues.
Two tryptic peptides representing the N terminus (residues 1–12) and
middle region (residues 13–38) of reduced and alkylated L-EGF were also
characterized. The N-terminal tryptic peptide (residues 1–12) was treated
with PGAP, and Edman degradation determined the sequence of residues
2–11. Matrix-assisted laser desorption/ionization time of flight mass spec-
trometry (MALDI-TOF MS), electrospray mass spectrometry (ES-MS),
and ES collisionally induced dissociation (ES-CID) determined the iden-
tity of residue 1 of the N-terminal peptide (residues 1–12). Edman degra-
dation confirmed the sequence of the second tryptic peptide (residues
13–38).
Reduction and alkylation of L-EGF. L-EGF peptide was denatured,
reduced, and cysteines alkylated with 4-vinylpyridine (Hawke and Yuan,
1987; Coligan et al., 1996). One microgram of peptide was dissolved in 17.5
ml of denaturing buffer (0.25 M Tris-HCl, 1.0 mM EDTA, and 6.0 M
guanidine-HCl, pH 8.5), and 2.5 ml of 10% 2-mercaptoethanol (Aldrich,
Milwaukee, WI) was added. After 2.5 hr at room temperature, 2 ml of neat
4-vinylpyridine (Aldrich) was added. After an additional 2 hr at room
temperature, the solution was taken to dryness under vacuum with a
SpeedVac concentrator (Savant Instruments, Inc., Hicksville, NY). The
residue was dissolved in 25 ml of 1% TFA and desalted on a Hewlett
Packard HP 1090 Liquid Chromatographic System using a 2.1 3 30 mm, 5
mm C18 column. The gradient solvents were aqueous 0.1% TFA (solvent
A) and ACN/water/TFA, 80:20:0.01 (solvent B). After injection of the 25
ml sample and washing with 100% A, the column was developed with a
linear gradient of 100% A to 25% A/75% B over 30 min at 0.175 ml/min.
The fraction containing the salt-free alkylated peptide was taken to dry-
ness in the vacuum concentrator and stored dry at 4°C. The peptide was
characterized by MALDI-TOF MS and ES-MS, and the reduced and
alkylated peptide was found to have gained 630 Da, indicating that six
cysteines had been alkylated (each pyridylethyl substitution adds 105 Da).
Reduction of L-EGF without alkylation. L-EGF peptide was denatured,
reduced, and purified following the above procedure but without alkyla-
tion. The reduced peptide was characterized by MALDI-TOF MS and
found to have gained 6 Da, indicating that three disulfide bonds had been
reduced.
Endoproteinase Glu-C digestion of alkylated L-EGF peptide. An aliquot of
reduced and alkylated L-EGF was digested with sequencing grade Glu-C
(Boehringer Mannheim, Indianapolis, IN) by established procedures (Co-
ligan et al., 1996). The resulting peptides were purified by C18 RP-HPLC
(4.6 3 250 mm; Vydac) using a gradient of 0.1% TFA and 100% ACN
containing 0.1% TFA and lyophilized, and the C-terminal Glu-C peptide
(residues 30–43) was subjected to Edman microsequence analysis.
Trypsin digestion of the alkylated L-EGF peptide. One microgram of
alkylated peptide was dissolved in 50 ml of 0.1 M ammonium bicarbonate,
0.025 mg of N-tosyl-phenylalanine chloromethyl ketone-treated trypsin
(Worthington, Freehold, NJ) was added, and the digestion reaction was
incubated at 37°C. The reaction was followed by MALDI-TOF MS and
was complete after 2 hr. After the addition of 1 ml neat TFA, the reaction
was fractionated by C18 RP-HPLC (2.1 3 30 mm column; PE/Applied
Biosystems) using a 15 min linear gradient of 0–75% ACN containing
0.1% TFA at 0.3 ml/min and monitored at 214 nm. Alternatively, the
reaction was fractionated by C18 RP-HPLC (2.1 3 150 mm column, 5 mm;
Vydac) using a linear gradient of 0–60% ACN containing 0.1% TFA.
Fractions were assayed for the desired alkylated peptide by MALDI-TOF
MS. Two peptides were obtained representing the N terminus (residues
1–12) and middle (residues 13–38) portions of the L-EGF peptide. Appro-
priate fractions were pooled, taken to dryness in the vacuum concentrator,
dissolved in 50% methanol /water containing 5% acetic acid, and further
analyzed by ES-MS, ES-CID (residues 1–12), MALDI-TOF MS, and
Edman degradation.
Pyroglutamate aminopeptidase digestion of alkylated N-terminal tryptic
peptide (residues 1–12). PGAP (Boehringer Mannheim) digestion of the
N-terminal tryptic peptide (residues 1–12) was performed in 100 mM
potassium phosphate, 10 mM EDTA, 5 mM dithioerythritol, and 5%
glycerol, pH 8.0. A ratio of 1 U of enzyme/mg of peptide was used, and the
mixture was incubated at 37°C overnight. The resulting peptide from the
above digests was desalted using a C18 ZipTip pipette tip (Millipore,
Danvers, MA). Aliquots of the desalted sample were taken for MALDI-
TOF MS and Edman degradation.
Mass spectrometry. ES-MS was performed in a Perkin-Elmer Sciex API
III triple-quadruple mass spectrometer (PE/Sciex, Thornfill, Ontario, Can-
ada). When desalting was required, a liquid chromatograph (PE/Applied
Biosystems model 140A) fitted with two 10 ml syringe cylinders was used
in series with the API III mass spectrometer. Desalting was performed on
an Aquapore Butyl C4 column (2.1 3 30 mm, 7 mm; PE/Applied Biosys-
tems) with a gradient of 2–70% ACN containing 0.05% TFA in 20 min.
MALDI-TOF MS was performed in a PE/PerSeptive Voyager-DE (PE/
PerSeptive BioSystems, Framingham, MA) using a-cyano-4-hydroxy-
cinnamic acid (Aldrich) for a matrix. The matrix-to-analyte ratio was
;1000:1 and the “dried drop technique” was used in spotting the sample
plate.
Cloning of L-EGF. Based on the L-EGF amino acid sequence, two
degenerate sense oligonucleotides, L-EGF-S1 (59-agaagcttggngcnaa(t /
c)tg(t /c)at(t /c /a)gcnta(t /c)gg-39) and L-EGF-S2 (59-agaagcttgcnat(t /c /
a)tg(t /c)ga(a/g)tg(t /c)ccntt(t /c)gg-39), were designed and used to PCR-
amplify a L-EGF cDNA fragment from an albumen gland-specific lZAPII
cDNA library. These primers were used in a nested PCR strategy in
combination with primers directed against either the right l arm (EV2,
59-cgccagggttttcccagtcacgac-39; and T77, 59-gcgtaatacgactcactatagggcga-39)
or the left l arm (EV3, 59-agcgataacaatttcacacagga-39; and T33, 59-
gcgcaattaaccctcactaaagg-39). The L-EGF primers contained at the 59 end
a recognition sequence for the restriction endonuclease HindIII. PCR was
performed in a 50 ml solution containing ;10 8 pfu of phenol-extracted and
ethanol-precipitated library DNA, 200 mM each of the four deoxynucleo-
tides, 50 pmol of L-EGF-s1, 12.5 pmol of EV2 or EV3, 20 mM Tris-HCl,
pH 8.4, 50 mM KCl, 3 mM MgCl2, and 0.5 U of Taq DNA polymerase
(Goldstar). The PCR mixture was incubated in a DNA thermal cycler
(Perkin-Elmer Cetus, Norwalk CT) for 42 cycles of 15 sec at 94°C, 30 sec
at 46°C, and 3 min at 72°C. Of this PCR mixture, 1 ml was reamplified for
35 cycles under the same conditions, now using primers L-EGF-s2 in
combination with T77 or T33. Amplified cDNA fragments were digested
with EcoRI and HindIII, separated on agarose gel, cloned into pBluescript
KS(1), and sequenced using an ABI 310 automated sequencer and the
ABI PRISM Dye Terminator Cycle Sequencing kit (Perkin-Elmer Cetus).
The cloned 300 bp L-EGF cDNA fragment was labeled with [a- 32P]dATP
by random priming and used as a probe to screen ;100,000 recombinant
clones of the albumen gland cDNA library. The clones were plated,
absorbed to replica nylon filters (Boehringer Mannheim), prehybridized at
65°C for 16 hr, and hybridized at 65°C for 60 hr. The prehybridization and
hybridization solutions contained 63 SSC (13 SSC: 150 mM NaCl and 15
mM sodium citrate, pH 7.4), 53 Denhardt’s solution, 0.1% SDS, and 100
mg/ml salmon sperm DNA. The filters were washed two times in 13
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SSC/0.1% SDS at 65°C for 15 min, and hybridization signals were visual-
ized using a GS-525 Molecular Imager System and Multi-Analyst 1.0
imaging software (both from Bio-Rad, Hercules, CA). Positive clones were
isolated, and the insert-containing pBluescript phagemid (pBS-L-EGF)
was rescued by in vivo excision and sequenced on both strands using
vector-based primers and internal primers.
CNS organ culture. Adult Lymnaea CNS were dissected, washed 30 min
in antibiotic saline (in mM: 51.3 NaCl, 1.7 KCl, 4.1 CaCl2, 1.5 MgCl2, and
5 HEPES, pH 7.9) containing 150 mg/ml gentamicin (Sigma, St. Louis,
MO), and cultured for 24 hr in a modified Leibovitz L-15 defined medium
(DM) (special order; Life Technologies, Rockville, MD) (Ridgway et al.,
1991).
Northern blot analysis. Total RNA was isolated from albumen glands,
acutely dissected adult CNS, and cultured adult CNS, using the guanidine
isothiocyanate method (Chomczynski and Sacchi, 1987), and 15–20 mg of
RNA was glyoxylated, fractionated on a 1.2% agarose gel, and transferred
to a charged nylon membrane (Boehringer Mannheim). After prehybrid-
ization for 4 hr, the filter was hybridized at 65°C for 16 hr with a full-length
[a- 32P]dATP-labeled L-EGF cDNA probe (specific activity, .10 8 dpm/
mg) and washed in 0.23 SSC, 0.1% SDS at 65°C for 30 min, and hybrid-
ization signals were visualized using a GS-252 Molecular Imager System
and Multi-Analyst 1.0 imaging software.
Reverse transcription-PCR. Total RNA was isolated from cultured adult
CNS, acutely dissected adult CNS (from animals 10 weeks of age; shell
length of 20–25 mm), acutely dissected juvenile CNS (from animals 3–4
weeks of age; shell length of 8–10 mm), albumen glands as above, or egg
masses at various developmental stages. In each case, 1–2 mg of RNA was
reverse transcribed into oligo-dT17-primed cDNA using 200 U of M-MLV
reverse transcriptase (SuperScript II; Life Technologies). A 256 bp L-EGF
cDNA fragment was amplified using primers L-EGF-S3 (59-tggtgc
gaattgtattgcctatgg-39) and L-EGF-AS1 (59-ctttacaagttcataaccttatagtc-39).
As positive controls for the cDNA synthesis, Lymnaea fructose 1,6-
biphosphate aldolase cDNA was amplified using primers Lald-6 (59-gctg-
gtcaaggatgcccc-39; sense) and Lald-4 (59-tagcttgtagagctcggccat-39; anti-
sense) (Van Kesteren et al., 1998), or Lymnaea tubulin cDNA was
amplified using primers Ltub-s1 (59-aggcggaatccaacatgaac-39) and Ltub-
as1 (59-cccctcagcttcttcctcatc-39). PCR reactions were performed as de-
scribed above. Thirty cycles (egg mass cDNA) or forty cycles (all other
templates) were performed for 30 sec at 94°C, 30 sec at 58°C, and 30 sec at
72°C. Twenty microliters of the PCR mixtures were separated on a 2%
agarose gel and photographed.
Neuron isolation and outgrowth assays. Identified neurons were isolated
from the CNS of adult Lymnaea (10–14 weeks of age; shell length of 20–25
mm). Individual neurons were isolated according to the procedure de-
scribed by Wildering et al. (1998). Neurons were cultured in DM, DM plus
L-EGF, DM plus hEGF, or Lymnaea brain conditioned medium (CM)
(Ridgway et al., 1991). Purified and lyophilized L-EGF or recombinant
hEGF (PreproTech EC, Rocky Hill, NJ; gift of Dr. S. Weiss, University of
Calgary, Calgary, Canada) were dissolved in DM to a final concentration
in the plate of 100 nM (unless otherwise indicated). The protein kinase
inhibitors K-252a (Kamiya, Seattle, WA) and PD153035 (gift of Dr. M.
Hollenberg, University of Calgary; or supplied by Calbiochem-
Novabiochem, San Diego, CA) were dissolved in DMSO before addition to
the culture medium. The final DMSO concentrations in the plate were 0.02
and 0.1% v/v for K-252a and PD153035, respectively. Control plates
contained the same concentration of DMSO, and all reagents were added
before the isolation procedure. Neurons were plated in specially prepared
polystyrene culture dishes (Falcon #3001; Becton Dickinson Labware,
Franklin Lakes, NJ) containing a poly-L-lysine-coated small-volume (150
ml) center well (Wildering et al., 1998). To minimize evaporation from the
center well, the outer part of the dish was also filled with DM without
allowing contact between the inner and outer compartment. A variety of
neurons were isolated and cultured for the outgrowth assays: right Parietal
A cluster (RPA) and Pedal A cluster (PeA) motoneurons, the peptidergic
neuron right Parietal Dorsal 2 (RPD2) and peptidergic neurons from the
right Parietal B cluster (RPB), the dopaminergic interneuron right Pedal
Dorsal 1 (RPeD1), and the identified neurons Visceral Dorsal 2 and 3
(VD2/3). Neurons were considered to have extended neurites if they
showed at least one primary neurite of more than one soma diameter in
length with an active growth cone. Neurite outgrowth was scored ;48 hr
after isolation, and all sessions included a control. Every outgrowth result
of each experiment was derived from multiple isolation sessions. The
identity of the dishes was unknown to the individuals involved in the
plating as well as the scoring of outgrowth. The dose–response data
regarding L-EGF-induced neurite outgrowth in RPA neurons were fitted
with a nonlinear regression routine (Leverberg–Marquardt method) to a
four-parameter logistic equation (i.e., sigmoidal dose–response curve with
variable slope). The dose–response data regarding the inhibition of
L-EGF-induced neurite outgrowth by the protein kinase inhibitor K-252a
was analyzed by means of a x 2 test for trend. Effects of single doses of
K-252a or PD153035 on CM-, L-EGF- and hEGF-induced neurite out-
growth were analyzed by a Fisher’s exact test. The number of neurons (n)
given in the text or figure legends reflects the total, pooled number of
neurons plated under that condition (i.e., the sum of multiple isolation
sessions). The percentages of neurite outgrowth are presented with their
95% confidence intervals (CI95%) of ratios as calculated from the F
distribution according to Sachs (1982). The two-sided critical value of
statistical significance was p , 0.05.
RESULTS
Human EGF promotes neurite outgrowth from
molluscan neurons
We tested the hypothesis that EGF can exert neurotrophic actions
in adult Lymnaea neurons. To address this issue, we first assayed
recombinant hEGF in our in vitro system. Previous studies showed
that Lymnaea CM, murine 2.5 S nerve growth factor (NGF), and
several extracellular matrix factors induce neurite outgrowth from
RPA motoneurons in culture (Ridgway et al., 1991; Wildering et
al., 1998). These neurons are readily isolated in large numbers and
were used in our initial neurite outgrowth assays. RPA neurons
were cultured in DM with the addition of 1 (n 5 29), 10 (n 5 29),
or 100 (n 5 28) nM hEGF (Fig. 1). In general, RPA neurons did not
show neurite extension when cultured in DM (n 5 31) (Fig. 1A,
lef t, B; also see Fig. 5). Addition of hEGF to the culture medium
induced neurite outgrowth in a percentage of the RPA motoneu-
rons (Fig. 1A, right). Concentrations of 1, 10, and 100 nM hEGF
induced outgrowth in 17, 21, and 32% of RPA neurons, respec-
tively (Fig. 1B). These data show that hEGF can act as a neuro-
trophic factor on adult Lymnaea motoneurons, suggesting the ex-
istence of an endogenous Lymnaea EGF homolog.
Purification and characterization of Lymnaea EGF
Mammalian EGF is known to be involved in the control of cell
proliferation and differentiation during development (Plata-
Salama´n, 1991; Gage et al., 1995; Weiss et al., 1996; Yamada et al.,
Figure 1. Human EGF induced neurite outgrowth in RPA motoneurons.
A, Photomicrographs of RPA motoneurons cultured for 48 hr in either DM
(lef t panel ) or DM plus 100 nM hEGF (right panel ). The addition of hEGF
to the culture medium induced neurite outgrowth in this type of neuron.
Scale bar, 50 mm. B, Different concentrations of hEGF induced neurite
extension in RPA motoneurons after 48 hr in culture. The percentages are
presented with their 95% confidence intervals.
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1997; Temple and Alvarez-Buylla, 1999). Thus, a potential source
of Lymnaea EGF are the glands that secrete fluids surrounding the
fertilized oocytes before they are packaged into egg masses (e.g.,
albumen gland, oothecal gland; Joosse and Geraerts, 1983). We
prepared protein extracts from albumen glands and separated these
using RP-HPLC. A representative RP-HPLC elution is shown in
Figure 2A. A major absorbance peak corresponding to fraction 1
was reduced and alkylated and then further purified by RP-HPLC
using a different counterion (Fig. 2B). The amino acid composition
analysis indicated that purified fraction 1 (Fig. 2B) contained a
peptide that was 40–43 residues in length (Table 1). Microse-
quence analysis and mass spectrometry confirmed a length of 43
residues and demonstrated that this peptide is 35% identical (47%
with conserved substitutions) with mouse EGF, including the EGF-
like six cysteine residues and three C-terminal residues (Table 2,
Fig. 3A). Therefore, we named this peptide L-EGF.
The observed mass of native L-EGF agrees with that calculated
for the determined sequence of the native structure containing
three disulfide bonds (Table 2), thus precluding any additional
residues or additional post-translational modifications. A sequence
comparison of L-EGF with other members of the EGF family
shows a strict conservation of all six cysteine residues (positions 8,
13, 19, 28, 30, and 39), as well as the three characteristic EGF-like
residues in the C-terminal region (Tyr34, Gly36, and Arg38) (Fig.
3A) (Carpenter and Cohen, 1990). The spacing between the first–
second and third–fourth cysteine residues differs from the verte-
brate EGF family members but is identical to the EGF-like motifs
that are found in molecules such as Notch and Delta (Fig. 3A).
Cloning and structural characteristics of L-EGF
PCR on independent fractions of an albumen gland-specific cDNA
library with degenerate oligonucleotide primers in combination
with vector-based primers resulted in the identification of a single
300 bp PCR product in each fraction. Nucleotide sequencing of this
product revealed that it encoded the C-terminal region of L-EGF,
as predicted by the amino acid sequence data, followed by a stop
codon, a short 39 untranslated region of 216 bp, and a poly(A1) tail.
Using this cDNA fragment as a probe, the full-length L-EGF
cDNA was isolated from one of the library fractions and completely
sequenced on both strands. The full-length L-EGF cDNA is 451 bp
in length and contains a single open reading frame encoding a 64
amino acid protein, preceded by several in-frame stop codons,
indicating that the open reading frame is complete at the 59 end
(Fig. 3B).
The predicted L-EGF precursor protein consists of a 21 amino
acid signal peptide, which is predicted to be cleaved after Ala21
(Von Heijne, 1983). The remaining EGF domain is 43 amino acids
in length and is identical to the amino acid sequence of the purified
L-EGF peptide (compare Fig. 3B with Fig. 3A and Table 2).
Comparison of the L-EGF precursor with other vertebrate and
invertebrate members of the EGF family of growth factor precur-
sors (e.g., hEGF, TGFa, amphiregulin, and spitz) and precursors
with EGF motifs not belonging to the EGF family, such as Notch 3
and Delta 1, shows that the L-EGF precursor is surprisingly simple
(Fig. 3C). Whereas these other precursors are large and complex
multiple-domain proteins, most of which have a transmembrane
domain, the L-EGF precursor contains only a signal peptide and a
single copy of L-EGF. Conspicuously, the L-EGF precursor lacks a
transmembrane domain, setting it apart from all other members of
the EGF family. The presence of a signal peptide together with the
absence of a transmembrane domain strongly suggest that L-EGF
is a secreted peptide.
L-EGF expression in ovo, albumen gland, juvenile, and
organ-cultured adult CNS
Northern blot hybridization using the full-length L-EGF cDNA as
a probe revealed a very abundant transcript of ;450 bp in the
albumen gland, but no L-EGF transcript was detected in the adult
CNS either when acutely dissected or after organ culture for 24 hr
(Fig. 4A). The size of the transcript detected in albumen glands
corresponds well with the size of the cloned L-EGF cDNA, con-
firming that this clone is indeed full-length.
Because the L-EGF mRNA might be expressed in the CNS at
levels below the detection limit of a Northern blot hybridization, we
extended our expression studies to reverse transcription (RT)-PCR
analysis of cDNA derived from albumen gland, juvenile CNS,
acutely dissected adult CNS, and organ-cultured adult CNS (Fig.
4B) (see Material and Methods). In agreement with the Northern
blot hybridization, L-EGF cDNA could be amplified from albumen
glands but not from acutely dissected adult CNS. RT-PCR re-
vealed, however, abundant expression of L-EGF mRNA in juvenile
CNS and an upregulation of L-EGF mRNA levels in the organ-
cultured adult CNS (Fig. 4B, top panel). As a positive template
control, Lymnaea fructose 1,6-biphosphate aldolase was amplified
with consistency from all cDNA preparations (Fig. 4B, bottom
panel).
The expression of L-EGF in the albumen gland and the devel-
oping juvenile CNS suggests a role for L-EGF during embryonic
development. Therefore, we next examined the expression of
L-EGF mRNA in egg masses at different times from day 3 after
deposition [embryonic day 3 (E3)] to the day of hatching (E13).
Expression of L-EGF mRNA could be detected in all stages of in
Table 1. Amino acid composition of Lymnaea EGF
Amino acid
Residues/mol peptide
Composition Sequencea
Aspartic acid 5.1 (5) 5
Glutamic acid 4.1 (4) 5
Serine 3.0 (3) 3
Glycine 5.6 (5–6) 6
Arginine 2.0 (2) 2
Threonine 1.0 (1) 1
Alanine 3.3 (3) 3
Proline 3.1 (3) 3
Tyrosine 3.3 (3) 3
Valine 0.8 (1) 1
Cysteine 5.5 (5–6) 6
Isoleucine 4.5 (4–5) 4
Phenylalanine 1.1 (1) 1
Total 40–43 43
aResidues quantitated by HPLC.
Figure 2. Purification of Lymnaea EGF. A, C18 RP-HPLC profile of an
extract of 10 Lymnaea albumen glands that was fractionated using a gradi-
ent of 0.1% HFBA and ACN containing 0.1% HFBA. B, Fraction 1 in A
was reduced, alkylated, and purified using a gradient of 0.1% TFA and
ACN containing 0.1% TFA. The absorbance profile suggested that the
peptide had been purified to homogeneity, which was confirmed by subse-
quent microsequence and mass spectrometric analyses (Table 2). Fractions
containing L-EGF are indicated by solid bars.
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ovo development (Fig. 4C, top panel). As a positive template
control, Lymnaea tubulin was amplified consistently from all cDNA
preparations (Fig. 4C, bottom panel).
L-EGF induces neurite outgrowth
The upregulation of L-EGF mRNA in axotomized adult CNS
suggests a role for L-EGF in injury repair. Thus, we examined
whether L-EGF has neurotrophic activity in Lymnaea. To this end,
RPA motoneurons were cultured in DM containing L-EGF at
concentrations ranging from 300 pM to 1 mM (n . 25 for each
concentration) (Fig. 5). As a control, RPA neurons were cultured in
DM only (n 5 89). Our experiments showed that L-EGF induced
neurite outgrowth from RPA neurons in a dose-dependent manner.
The trophic activity of the peptide extended over a three log range
of concentrations (Fig. 5). The threshold dose was ;1 nM, whereas
the response reached a plateau at ;1 mM, with an EC50 of 22 nM
(CI95% of 8.8–54 nM) (Fig. 5). In accord with previous studies, only
a small percentage (,5%) of the neurons cultured under control
Table 2. Chemical and mass spectrometric sequence analysis of Lymnaea stagnalis EGF
Treatment Fragment Sequence
Calculated
observations
Mass Da
(average) Procedures
None (1–43) 4541.0a 4540.8 ES-MS
4540.9 MALDI
Reduced (1–43) 4547.0 4546.9 MALDI
Red. & Alk. (1–43) 5177.9 5177.5 MALDI
Red. & Alk./70% formic (7–41) PXQIVRXSYGANXIAYGDTAIXEXPFGYSGIRXQ Edman
Tr. of Red. & Alk. (1–12) 1404.5 1404.7 MALDI
1403.8 ES-MS
(1–12) ,QGDGEDPXQIVR ES-CID
(13–38) XSYGANXIAYGDTAIXEXPFGYSGI 3155.7 3155.4 Edman, MALDI
PGAP of (1–12) (2–12) GDGEDPXQIV 1293.4 1293.6 Edman, MALDI
Red. & Alk./Glu-C (30–43) XPFGYSGIRXQDPS Edman
Sequence (1–43) ,QGDGEDPCQIVRCSYGANCIAYGDTAICECPFGYSGIRCQDPS
u u u u u
1 10 20 30 40
^Q, Pyrrolidone carboylic acid; Red. & Alk., reduction and alkylation; X, pyridylethyl cysteine; Tr, trypsin; Glu-C, endoproteinase Glu-C.
aCalculated as oxidized peptide; therefore, three disulfide bonds.
Figure 3. cDNA and deduced amino acid sequence of
L-EGF and alignment of L-EGF with vertebrate and
invertebrate EGF-related proteins and precursor mol-
ecules. A, Amino acid sequence alignment of L-EGF
and EGF-like motifs from mouse EGF (mEGF ) (Gen-
Bank accession number GI494001; Savage et al.,
1972), hEGF (GenBank accession number
NP 001954; Bell et al., 1986), human transforming
growth factor a (hTGFa) (GenBank accession num-
ber AAA61158; Derynck et al., 1984), human amphi-
regulin (amphiregulin) (GenBank accession number
NP 001648; Plowman et al., 1990), human Delta-1
(Delta 1) (GenBank accession number NP 005609;
unpublished), and human Notch 3 (Notch 3) (Gen-
Bank accession number NP 000426; Lewis, 1996).
Note the conservation of all six cysteine residues (po-
sitions 8, 13, 19, 28, 30, and 39), as well as the charac-
teristic EGF-like residues in the C terminal, i.e.,
Tyr 34, Gly 36, and Arg 38. B, cDNA sequence and de-
duced amino acid sequence of L-EGF. Nucleotide
positions are numbered at the right; amino acid posi-
tions are numbered below the amino acid sequence.
The first amino acid of the signal sequence and of the
L-EGF domain are indicated by arrows. In frame, stop
codons in the 59 untranslated region are underlined;
asterisk denotes the stop codon; a putative polyadenyl-
ation signal in the 39 untranslated region is in bold. C,
Comparison of the L-EGF precursor molecule with
other EGF(-like) precursor molecules, i.e., TGFa, am-
phiregulin, Drosophila spitz, hEGF, Notch 3, and
Delta 1. Gray blocks indicate EGF-like motifs; dotted
blocks indicate non-EGF-like repeat motifs. SP, Signal
peptide; TM, transmembrane domain.
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conditions (i.e., DM alone) exhibited neurite outgrowth (Ridgway
et al., 1991; Wildering et al., 1998) (Figs. 1A,B, 5).
Specificity of L-EGF-induced neurite outgrowth
We expanded our study to ask whether L-EGF could induce
outgrowth from neurons other than RPA motoneurons. To this
end, we isolated and cultured a number of different types of
identified neurons: another group of motoneurons (PeA neurons),
two types of neurosecretory cells (RPB neurons and the unique cell
designated as RPD2), and an interneuron (RPeD1, also known as
the giant dopamine cell). We also examined a pair of identical
neurons, VD2/3, which are of unknown function but whose mor-
phology suggests a visceral function (Magoski and Bulloch, 1997).
As a positive control, neurons were cultured in CM, which is a
potent stimulator of neurite outgrowth in all types of Lymnaea
neurons tested to date (Ridgway et al., 1991). As expected, all of
the six types of neurons tested in CM exhibited robust outgrowth
after 1–2 d of culture (Fig. 6). The morphology of cells that
responded to CM (Fig. 6A) was similar to previous studies (Ridg-
way et al., 1991; Wildering et al., 1998). In contrast, L-EGF in-
duced neurite outgrowth in only three of the six cell types tested,
these being the RPA and PeA motoneurons and the visceral
neurons VD2/3 (Fig. 6). The appearance of the sprouted cells was
strikingly different in L-EGF compared with CM but was similar to
that observed in hEGF; the neurites were relatively thick and short,
i.e., the axons often extended only a few soma diameters in length,
even after extended culture periods (Figs. 1A, 6A). Despite these
different morphological phenotypes, the percentage of cells that
responded to L-EGF was not different from CM (Fig. 6B). The
three cell types that did not respond to L-EGF (i.e., RPB, RPD2,
and RPeD1) always remained spherical without any sign of process
outgrowth (Fig. 6A).
L-EGF signaling
Given that EGF is known to signal via a tyrosine kinase receptor
in vertebrate cells (Yamada et al., 1997), we assayed the effects of
kinase inhibitors on L-EGF- and hEGF-evoked responses (Fig. 7).
RPA motoneurons were cultured in the presence of either L-EGF
(100 nM) or hEGF (100 nM) with (experimental) or without (con-
trol) the addition of K-252a, a broad-spectrum protein kinase
inhibitor (Fig. 7A) (Kase et al., 1986, 1987; Ruegg and Burgess,
1989; Knu¨sel and Hefti, 1992). A similar percentage of the neurons
cultured in the presence of L-EGF (49%, n 5 47) (Figs. 5, 6) or
hEGF (32%, n 5 38) (Fig. 1B) exhibited neurite outgrowth (Fig.
7A). In the presence of the inhibitor, L-EGF-induced neurite
outgrowth was significantly reduced in a dose-dependent manner
( p , 0.0001). The addition of 10 nM K-252a (n 5 39) reduced the
responsiveness of neurons to L-EGF. The addition of 100 nM
K-252a completely blocked neurite outgrowth, and the neurons
remained spherical in both L-EGF (n 5 38) and hEGF (n 5 46,
p , 0.0001) (Fig. 7A).
Second, we tested the effects of PD153035, a tyrosine kinase
inhibitor reported to be specific for the EGF receptor (EGFR) (Fry
et al., 1994), on outgrowth induced by CM, 100 nM L-EGF, or 100
nM hEGF (Fig. 7B). Without inhibitor, 56, 43, and 38% of the
neurons showed neurite outgrowth in CM (n 5 50), L-EGF (n 5
84), or hEGF (n 5 39), respectively (Fig. 7B). Importantly, the
addition of 100 nM PD153035 did not affect the outgrowth of RPA
Figure 4. L-EGF expression in the developing and adult CNS. A, North-
ern blot hybridization of adult CNS, injured cultured adult CNS, and
Lymnaea albumen gland show only transcript of a 450 nucleotides in the
albumen gland. No L-EGF mRNA was found in the acutely dissected or
injured cultured adult CNS. B, RT-PCR analysis of expression of L-EGF in
the albumen gland, juvenile CNS, and injured cultured adult CNS. Acutely
dissected adult CNS did not express L-EGF. Oligonucleotide primers
against fructose 1,6-biphosphate aldolase generated a PCR product of the
expected size in all tissues. PCR water controls are shown in the right lanes.
C, RT-PCR analysis of expression of L-EGF in developing Lymnaea em-
bryos. L-EGF mRNA expression was observed in egg masses from 3 d after
egg mass deposition (E3) up to hatching (E13). Oligonucleotide primers
against Lymnaea tubulin generated a PCR product of the expected size in
all tissues. PCR water controls are shown in the right lanes.
Figure 5. Dose–response curve of Lymnaea EGF. Neurite outgrowth in
RPA neurons after 48 hr in culture. The lowest concentration of L-EGF
that induced neurite outgrowth was ;1 nM, whereas maximal outgrowth
was observed at 1 mM. The EC50 (open circle) as derived from the fitted
model was 22 nM. The 95% confidence interval of the EC50 was 8.8–54 nM
(horizontal bar). The number of neurons cultured per concentration was
.25. The total number of neurons cultured in L-EGF was .230.
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neurons in CM (n 5 48, p 5 0.69) (Fig. 7B), indicating that the
inhibitor had no nonspecific adverse effect on the cells. The pres-
ence of PD153035, however, significantly reduced the percentage
of neurons extending neurites in L-EGF (n 5 90, p , 0.0005) (Fig.
7B) and in hEGF (n 5 46, p , 0.025) (Fig. 7B).
DISCUSSION
In this study, we purified and cloned a Lymnaea epidermal growth
factor homolog (L-EGF) and characterized its neurotrophic ac-
tions. Expression patterns suggest that L-EGF has a developmental
role in embryos and in the juvenile CNS and is involved in injury
response of the adult CNS. The latter notion is supported by our
Figure 6. Specificity of L-EGF-induced neurite outgrowth. A, Photomi-
crographs of different types of neurons cultured for 48 hr in either CM (lef t
panels) or DM with 100 nM L-EGF (right panels). RPA motoneurons, the
neurosecretory neuron RPD2, the dopaminergic interneuron RPeD1, and
the neurons VD2/3 developed multiple neurites when cultured in CM. In
contrast, only RPA neurons and VD2/3 showed neurite outgrowth in the
presence of 100 nM L-EGF. The neurons RPD2 and RPeD1 remained
spherical. Scale bar, 50 mm. B, The percentage of neurons developing
neurites after culturing for 48 hr in either CM (open bars) or DM plus 100
nM L-EGF (hatched bars). The majority of RPA and PeA motoneurons
(n 5 46 and 13, respectively), the neurosecretory RPB neurons (n 5 21) and
RPD2 (n 5 13), the interneuron RPeD1 (n 5 11), and the identified VD2/3
(n 5 14) showed neurite outgrowth in the presence of CM. When cultured
in the presence of 100 nM L-EGF, only RPA (n 5 39) and PeA (n 5 14)
motoneurons and VD2/3 (n 5 15) extended neurites. The RPB neurons
(n 5 30) and the identified neurons RPD2 (n 5 15) and RPeD1 (n 5 12)
always remained spherical in the presence of 100 nM L-EGF. The percent-
ages are presented with their 95% confidence intervals.
Figure 7. Receptor tyrosine kinase-mediated L-EGF signaling in RPA
motoneurons. A, The protein kinase inhibitor K-252a significantly reduced
L-EGF-induced neurite outgrowth in a dose-dependent manner (x2 test for
trend) and hEGF-induced neurite outgrowth (Fisher’s exact test). The
percentages are presented with their CI95%. B, The specific EGFR tyrosine
kinase inhibitor PD153035 (100 nM) significantly reduced L-EGF- and
hEGF-induced neurite outgrowth (Fisher’s exact test). In contrast, CM-
evoked neurite outgrowth was not affected by 100 nM PD153035 ( p 5 0.69;
Fisher’s exact test). The percentages are presented with their 95% confi-
dence intervals. *p , 0.025; **p , 0.0005; ***p , 0.0001.
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finding that L-EGF evokes neurite outgrowth in some but not all
identified adult neurons in vitro, suggesting differential neurotro-
phic actions.
Molecular structure of L-EGF
The L-EGF precursor is rather unique and surprisingly simple
compared with the precursor of other EGF family members (e.g.,
EGF, TGFa, amphiregulin, spitz, and gurken) and other proteins
containing an EGF motif (e.g., Notch and Delta). The L-EGF
precursor molecule contains only a signal peptide and a single copy
of L-EGF and lacks a transmembrane domain. Whereas mamma-
lian EGF precursors require proteolytic processing to release EGF,
we predict that L-EGF is synthesized as a nonmembrane-bound
peptide and subsequently secreted.
Importantly, the cDNA clone of L-EGF predicts the same amino
acid sequence as the purified peptide. Together, the purification
and cloning data show that L-EGF has the typical arrangement of
six cysteine residues and three characteristic amino acid residues in
the C-terminal region (Tyr34, Gly36, and Arg38) that are found in
most EGF-related proteins (Carpenter and Cohen, 1990). The
cysteine residues form three intramolecular disulfide bonds that are
necessary for maintaining the biological activity of EGF (Taylor et
al., 1972; Savage et al., 1973). Although our data do not support any
assignment, the canonical EGF disulfide pattern would predict
cystinyl bridges between positions 8 and 19, 13 and 28, and 30 and
39 (Table 2).
Whereas EGF itself has only been reported in mammals, EGF-
like domains have been found in genes from a wide variety of
organisms ranging from the protist Plasmodium falciparum
(Kaslow et al., 1988) to invertebrate and vertebrate multizoa
(Greenwald, 1990; Muskavitch and Hoffmann, 1990; Yamada et al.,
1997). This suggests that the EGF motif has an ancient origin and
is conserved in eukaryotes. Although the six cysteine residues are
invariably present in all EGF-like domains, the spacing between
the first two pairs of cysteine residues varies (Greenwald, 1990;
Muskavitch and Hoffmann, 1990; Rutledge et al., 1992; Yamada et
al., 1997; Van de Poll et al., 1998). L-EGF in this regard shares a
higher similarity with the EGF-like repeats in proteins such as
Notch and Delta than with EGF itself (Fig. 3A). It is suggested that
size and composition of the cysteine loops are an important deter-
minant of receptor binding by EGF (Van de Poll et al., 1998).
However, although hEGF and L-EGF differ in their cysteine res-
idue spacing, the fact that both peptides induced neurite outgrowth
from Lymnaea neurons in vitro suggests that receptor-binding prop-
erties are conserved. This notion is supported by the observation
that the neurotrophic effect of both L-EGF and hEGF could be
inhibited by PD153035, a specific inhibitor of the EGFR (see
Results and below, L-EGF signaling).
Developmental significance of L-EGF
Mammalian EGF is expressed in the developing and adult CNS
(Rall et al., 1985; Schaudies et al., 1989; Lazar and Blum, 1992). In
this study, we showed that L-EGF is synthesized and that its
mRNA is expressed at high levels in the albumen gland of adult
Lymnaea. The albumen gland is part of the female reproductive
tract, and it secretes the perivitelline fluid that surrounds the
fertilized oocytes (for review, see Joosse and Geraerts, 1983).
Moreover, L-EGF mRNA is expressed throughout embryonic de-
velopment. With regard to neurogenesis it is interesting to note
that, at stage E3, cell groups from the ectodermal epithelium begin
to differentiate into ganglion cells and the first elements of the
nervous system appear (Verdonk, 1973; Croll and Voronezhskaya,
1996). Thus, L-EGF is already expressed during the earliest stages
of neurogenesis. This notion is further supported by preliminary
RP-HPLC and mass spectrometry data indicating that intact
L-EGF is present in the egg masses, from either embryonic or
maternal origin (G. T. Nagle, unpublished observations). Together,
this strongly suggests a role for L-EGF during embryonic devel-
opment of Lymnaea.
In addition to the albumen gland, high levels of L-EGF mRNA
are expressed in the CNS of animals ;3–4 weeks after hatching. In
Lymnaea, development of the CNS is incomplete at hatching, and
neuronal proliferation, circuit formation, and other developmental
phenomena continue for 6–8 weeks after hatching (Croll and
Chiasson, 1989; Smit et al., 1992; Serfozo et al., 1998; Croll et al.,
1999). Thus, the expression of L-EGF in the CNS during extraovu-
lar development of the nervous system strongly suggests a role of
L-EGF in maturation of the juvenile CNS. Together, our data
suggest neurotrophic and proliferative roles for L-EGF both dur-
ing the development of the Lymnaea embryo and in the juvenile
CNS. This view complements studies in mammals that point to
proliferative and neurotrophic roles for vertebrate EGF during
CNS development (for review, see Plata-Salama´n, 1991; Yamada et
al., 1997). For example, mammalian EGF is thought to be involved
in the regulation of cell proliferation and differentiation (for re-
view, see Gage et al., 1995; Weiss et al., 1996; Temple and Alvarez-
Buylla, 1999), as well as in the survival and process outgrowth of
embryonic neurons (Morrison et al., 1987; Abe et al., 1991; Casper
et al., 1991; Maiese et al., 1993).
Neurotrophic actions of L-EGF
Whereas some neurotrophic actions of vertebrate EGF in the
developing CNS are described (see above), the neurotrophic func-
tion of EGF in the adult CNS is less well defined. In our study,
mRNA expression of L-EGF was not detectable in the acutely
isolated adult CNS. However, L-EGF is transcribed in the adult
CNS after it was isolated (a procedure that axotomizes most
neurons) and maintained for 24 hr in organ culture. Thus, our data
imply that L-EGF is involved in injury response in the adult CNS.
This is supported by our observation that L-EGF supports neurite
outgrowth from adult Lymnaea neurons and the report that
L-EGF, in a concentration range of 400–800 nM, can support
soma–soma synapse formation of adult Lymnaea neurons in vitro
(Hamakawa et al., 1999). The only other suggestion for such a role
of EGF is by Toma et al. (1992) who showed spatiotemporal
upregulation of the EGFR in Schwann cells and fibroblasts after
transection of the sciatic nerve in adult rats. This observation
indicates that EGF or one of the other EGFR ligands (e.g., TGFa,
amphiregulin, betacellulin, epiregulin, and heparin-binding epider-
mal growth factor-like factor) (for review, see Riesse and Stern,
1998), might enhance axonal regeneration.
We showed that L-EGF is able to differentially induce neurite
outgrowth in Lymnaea neurons. The specificity of L-EGF in vitro
appears to differ from both murine NGF and rat CNTF. Whereas
L-EGF induced neurite outgrowth primarily in Lymnaea motoneu-
rons, both NGF and CNTF induced neurite outgrowth in mo-
toneurons and interneurons (Ridgway et al., 1991; Syed et al.,
1996). CNTF also induced neurite outgrowth in a small percentage
of neurosecretory cells. Together, these studies suggest that, at
least in vitro, growth factor receptors are differentially expressed in
Lymnaea neurons. Furthermore, it suggests that some adult mol-
luscan neurons express multiple growth factor receptors, a feature
shared with many mammalian neurons (Korsching, 1993).
L-EGF signaling
Given that EGF acts via a tyrosine kinase receptor in vertebrate
cells, we assayed the effects of protein kinase inhibitors on L-EGF-
evoked neurite outgrowth. We showed that L-EGF-induced neu-
rite outgrowth of RPA neurons can be inhibited by a broad-
spectrum protein kinase inhibitor, K-252a (Kase et al., 1986, 1987;
Ruegg and Burgess, 1989; Knu¨sel and Hefti, 1992). This is consis-
tent with findings by others showing that EGF-dependent actions
on primary cultures of hippocampal and cerebellar neurons can be
inhibited by K-252a (Abe et al., 1992).
An even more convincing indication for the involvement of an
EGFR in L-EGF-evoked neurite outgrowth is the demonstration
that PD153035, reported to be a specific inhibitor of the EGFR
(Fry et al., 1994; Tropepe et al., 1999), inhibits L-EGF-induced
neurite outgrowth in RPA motoneurons. In view of the specificity
of the inhibitor, our observation that hEGF-induced neurite out-
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growth can be inhibited by PD153035 indicates that L-EGF and
hEGF act via the same receptor. Intriguingly, PD153035 did not
affect CM-induced neurite outgrowth in RPA motoneurons. This
could indicate that either L-EGF is not present in CM and other
growth factors with overlapping activities fully substitute for the
absence of L-EGF, or L-EGF is present but its neurotrophic
actions are masked by other growth factors present in CM. Alter-
natively, it may indicate that CM does not contain functional
L-EGF because of its degradation during production of CM (Ridg-
way et al., 1991). The hypothesis that L-EGF is present in CM,
whether in active or inactive form, corresponds more closely with
the observation that L-EGF mRNA expression is upregulated in
organ-cultured CNS, i.e., the source of CM-contained growth
factors. Moreover, this idea is supported by our observation that
L-EGF-induced neurite outgrowth is morphologically different
from CM-induced outgrowth in the same types of cells, as well as
by another study implicating other types of growth factors in the
control of neurite outgrowth in Lymnaea (Ridgway et al., 1991).
In conclusion, our data introduce L-EGF as the first secreted
form of EGF in invertebrates and suggest the involvement of
L-EGF in injury response. Furthermore, high levels of L-EGF
mRNA expression in ovo as well as in juvenile CNS suggests a
significant role for this peptide in development of the Lymnaea
nervous system. Moreover, our results indicate that the neurotro-
phic actions of EGF are likely to have an ancient origin. In view of
the apparent absence of neurotrophin family homologs in inverte-
brates, this raises the question as to whether the neurotrophic
actions of EGF evolved preceding those of other families of neu-
rotrophic factors.
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